Woodmont Investment Counsel LLC Sells 1,686 Shares of Bristol-Myers Squibb (NYSE:BMY)

Woodmont Investment Counsel LLC lowered its stake in Bristol-Myers Squibb (NYSE:BMY) by 9.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 16,919 shares of the biopharmaceutical company’s stock after selling 1,686 shares during the period. Woodmont Investment Counsel LLC’s holdings in Bristol-Myers Squibb were worth $918,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Northwest Financial Advisors bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $27,000. Pacific Capital Wealth Advisors Inc. bought a new position in Bristol-Myers Squibb in the fourth quarter valued at about $34,000. VisionPoint Advisory Group LLC grew its position in Bristol-Myers Squibb by 300.5% in the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 553 shares during the last quarter. Turtle Creek Wealth Advisors LLC bought a new position in Bristol-Myers Squibb in the fourth quarter valued at about $40,000. Finally, Wetzel Investment Advisors Inc. bought a new position in Bristol-Myers Squibb in the fourth quarter valued at about $40,000. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

BMY has been the topic of a number of recent analyst reports. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Barclays decreased their target price on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. Finally, StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 27th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Price Performance

Shares of BMY opened at $40.46 on Wednesday. Bristol-Myers Squibb has a 52-week low of $39.63 and a 52-week high of $65.38. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The business’s 50 day moving average price is $42.81 and its two-hundred day moving average price is $48.04. The firm has a market cap of $82.02 billion, a PE ratio of -13.05, a price-to-earnings-growth ratio of 14.21 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same period in the previous year, the firm earned $2.05 earnings per share. The company’s revenue was up 4.7% compared to the same quarter last year. On average, equities analysts anticipate that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.93%. The ex-dividend date is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.